January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–51. https://doi.org/10.1161/cir.0000000000000665.

Article  PubMed  Google Scholar 

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.

Article  PubMed  Google Scholar 

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. https://doi.org/10.1093/eurheartj/ehaa612.

Article  PubMed  Google Scholar 

Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):2247–59. https://doi.org/10.1016/j.chest.2021.07.056.

Article  PubMed  Google Scholar 

Wiggins BS, Dixon DL, Neyens RR, Page RL 2nd, Gluckman TJ. Select drug–drug interactions with direct oral anticoagulants: JACC review topic of the week. J Am Coll Cardiol. 2020;75(11):1341–50. https://doi.org/10.1016/j.jacc.2019.12.068.

CAS  Article  PubMed  Google Scholar 

Li A, Li MK, Crowther M, Vazquez SR. Drug–drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review. Thromb Res. 2020;194:240–5. https://doi.org/10.1016/j.thromres.2020.08.016.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Loo SY, Dell’Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–106. https://doi.org/10.1111/bcp.13299.

CAS  Article  PubMed  PubMed Central  Google Scholar 

van den Heuvel JM, Hövels AM, Büller HR, Mantel-Teeuwisse AK, De Boer A, Maitland-van der Zee AH. NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands. Thrombosis J. 2018;16(1):7. https://doi.org/10.1186/s12959-017-0156-y.

CAS  Article  Google Scholar 

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. https://doi.org/10.1016/s0140-6736(13)62343-0.

CAS  Article  PubMed  Google Scholar 

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. https://doi.org/10.1056/NEJMoa1107039.

CAS  Article  PubMed  Google Scholar 

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. https://doi.org/10.1056/NEJMoa0905561.

CAS  Article  PubMed  Google Scholar 

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. https://doi.org/10.1056/NEJMoa1310907.

CAS  Article  PubMed  Google Scholar 

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. https://doi.org/10.1056/NEJMoa1009638.

CAS  Article  PubMed  Google Scholar 

Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015;66(21):2271–81. https://doi.org/10.1016/j.jacc.2015.09.024.

CAS  Article  PubMed  Google Scholar 

Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017;103(8):623–8. https://doi.org/10.1136/heartjnl-2016-309901.

CAS  Article  PubMed  Google Scholar 

Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(11):1674-83.e3. https://doi.org/10.1016/j.cgh.2017.04.031.

CAS  Article  PubMed  Google Scholar 

Laine L. Bleeding with direct oral anticoagulants: the gastrointestinal tract and beyond. Clin Gastroenterol Hepatol. 2017;15(11):1665–7. https://doi.org/10.1016/j.cgh.2017.06.041.

Article  PubMed  Google Scholar 

Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48(9):2494–503. https://doi.org/10.1161/strokeaha.117.017549.

CAS  Article  PubMed  Google Scholar 

Gu ZC, Wei AH, Zhang C, Wang XH, Zhang L, Shen L, et al. Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18(4):792-9.e61. https://doi.org/10.1016/j.cgh.2019.05.056.

CAS  Article  PubMed  Google Scholar 

Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152(5):1014-22 e1. https://doi.org/10.1053/j.gastro.2016.12.018.

CAS  Article  PubMed  Google Scholar 

Adeboyeje G, Sylwestrzak G, Barron JJ, White J, Rosenberg A, Abarca J, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(9):968–78. https://doi.org/10.18553/jmcp.2017.23.9.968.

Article  PubMed  Google Scholar 

Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. Am J Cardiol. 2017;120(10):1813–9. https://doi.org/10.1016/j.amjcard.2017.07.092.

CAS  Article  PubMed  Google Scholar 

Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med. 2020;172(7):463–73. https://doi.org/10.7326/m19-2522.

Article  PubMed  Google Scholar 

Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362: k2505. https://doi.org/10.1136/bmj.k2505.

Article  PubMed  PubMed Central  Google Scholar 

Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019;85(2):422–31. https://doi.org/10.1111/bcp.13814.

CAS  Article  PubMed  Google Scholar 

Chan YH, Kuo CT, Yeh YH, Chang SH, Wu LS, Lee HF, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;68(13):1389–401. https://doi.org/10.1016/j.jacc.2016.06.062.

CAS  Article  PubMed  Google Scholar 

Lai CL, Chen HM, Liao MT, Lin TT, Chan KA. Comparative effectiveness and safety of dabigatran and rivaroxaban in atrial fibrillation patients. J Am Heart Assoc. 2017. https://doi.org/10.1161/jaha.116.005362.

Article  PubMed  PubMed Central  Google Scholar 

Ingason AB, Hreinsson JP, Ágústsson AS, Lund SH, Rumba E, Pálsson DA, et al. Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants : a nationwide propensity score-weighted study. Ann Intern Med. 2021;174(11):1493–502. https://doi.org/10.7326/m21-1474.

Article  PubMed  Google Scholar 

Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 2014;6:179–87. https://doi.org/10.2147/cpaa.S61131.

Article  PubMed  PubMed Central  Google Scholar 

Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S, et al. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. J Thromb Haemost. 2017;15(10):2017–28. https://doi.org/10.1111/jth.13801.

CAS  Article  PubMed  Google Scholar 

Lee SR, Choi EK, Kwon S, Han KD, Jung JH, Cha MJ, et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke. 2019;50(8):2245–9. https://doi.org/10.1161/strokeaha.119.025536.

CAS  Article  PubMed  Google Scholar 

Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J. 2012;76(9):2104–11. https://doi.org/10.1253/circj.cj-12-0454.

CAS  Article  PubMed  Google Scholar 

Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72. https://doi.org/10.1161/circulationaha.110.004747.

CAS  Article  PubMed  Google Scholar 

Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52. https://doi.org/10.1056/NEJMoa0906598.